Recombinant erIL-15 NK cell
Genetically modify NK cells to express and secrete IL-15 or its variants, combined with CD16 and CAR, the problem of NK-92 cells relying on exogenous factors is solved, and the function of no exogenous factor growth and immune stimulation in vivo is achieved. Simplify, reduce immunosuppression, and improve response to the tumor microenvironment.
Patent Information
- Application Number
- CN202411130590.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-03-15
- Filing Date
- 2020-02-27
- Publication Date
- 2024-11-29
AI Technical Summary
When used in vivo, existing genetically modified NK-92 cells rely on exogenous IL-2 or IL-15, resulting in high levels of secreted cytokines triggering immunosuppression, limiting their application in cancer treatment.
By genetically modifying NK cells to express and secrete IL-15 or its variants, combining CD16 and CAR, ensuring that sufficient IL-15 is produced in the cell to support growth and immune stimulation while avoiding systemic side effects, using recombinant nucleic acid-driven erLSP-IL -15 expression and secretion ensure that exogenous cytokines are not reliant on.
NK cells are grown and amplified under the condition of no exogenous factors, maintaining cytotoxicity and immune stimulation functions, simplifying the culture and amplification process, reducing immunosuppression, and improving the immune response to the tumor microenvironment.
Smart Images

Figure CN119040363A_ABST
Abstract
Description
[0001] This application is a divisional application of the Chinese invention patent application with application date of February 27, 2020, application number 202080010863.0, and invention name “Recombinant erIL-15NK cells”. Technical Field
[0002] The present disclosure relates to genetically modified immune cells that express IL-15, particularly when these genetically modified immune cells relate to NK cells that express and retain modified IL-15 within the cell and further express at least one of a high-affinity variant of CD16 and a CAR (chimeric antigen receptor). Background Art
[0003] The Background Description includes information that may be useful in understanding the present disclosure. No admission is made that any of the information provided herein is prior art or relevant to the presently claimed invention, nor is an admission made that any publication specifically or implicitly referenced is prior art.
[0004] All publications and patent applications are incorporated herein by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. Where a definition or use of a term in an incorporated reference is inconsistent or contrary to the definition of that term provided herein, the definition of that term provided herein applies and the definition of that term in the reference does not apply.
[0005] NK-92 cells are ideal in all aspects of cell-based therapies because they lack significant toxicity to allogeneic cells in the receptor and have a relatively wide spectrum of cytotoxic activity to a wide range of tumor cells. In addition, NK-92 cells can be cultured in a relatively simple manner, and are therefore an attractive option for adoptive cancer immunotherapy. Unfortunately, the proliferation and function of NK-92 cells are highly dependent on IL-2, which increases costs when NK-92 cells are needed on a large scale. In order to avoid problems associated with such cytokine requirements, NK-92 cells have been converted to express and retain IL-2 in the cell (see, e.g., Exp Hematol [experimental hematology] 33: 159-164). Although such modified cells do become independent of exogenous cytokines, there are still various disadvantages. Among other things, when such cells are used in mammals, IL-2 released by such modified cells can increase IL-2-mediated effects in vivo, which is particularly undesirable as IL-2 stimulates immunosuppression in the tumor microenvironment, typically through the growth and expansion of myeloid-derived suppressor cells (MDSCs) and T regulatory cells (Tregs).
[0006] In another example, NK-92 cells were transfected with cDNA cloned into the pcDNA3 expression vector to express IL-15 (see, e.g., Haematologica [Hematology], 2004; 89: 338-347), and the cells transfected in this way continuously produced high levels of IL-15 in the culture supernatant, which is believed to allow the cells to proliferate significantly faster in response to stimulation with low doses of IL-2 or IL-15. In addition, the cumulative number of cells in long-term culture was also significantly higher than that of untransfected cells. However, in the case of in vivo use of such cells, high levels of secreted IL-15 may present clinical problems.
[0007] Similarly, NK-92 cells are transformed using a viral transfection system to express a recombinant natural form of IL-15 (see, for example, Cancer Immunol Immunother [Cancer and Immunotherapy] (2012) 61: 1451-1461). Although such recombinant cells are able to grow and express recombinant CAR in the absence of exogenous cytokines, the transfection efficiency is relatively low, producing relatively low amounts of IL-15 in the cell, and secreting low amounts of IL-15 into the culture medium. In addition, compared with the parental NK-92 cell line, the cytotoxicity of the recombinant cells is reduced. It is worth noting that in the case of expressing the same IL-15 by a plasmid, the NK-92 cells thus produced are not completely independent of exogenous growth factors, thus limiting the in vivo use of such recombinant cells.
[0008] Therefore, even though various modified immune cells, especially modified NK cells, are known in the art, all or almost all of them have various disadvantages. Therefore, it is necessary to provide improved modified NK cells that exhibit ideal growth characteristics while maintaining targeted cytotoxicity. Summary of the invention
[0009] Disclosed herein are various recombinant cells, compositions, and methods in which NK cells are genetically modified to express and secrete or present IL-15 or a variant thereof intracellularly, thereby rendering the modified NK cells independent of exogenous cytokines and allowing stimulation / activation of other immune competent cells in proximity to the modified NK cells.
[0010] In one aspect of the inventive subject matter, the inventors contemplate a genetically modified NK cell and a method of making such a cell, wherein the genetically modified NK cell comprises a recombinant nucleic acid comprising a first segment encoding erLSP-IL-15. Most typically, the NK cell is a NK-92 cell and the recombinant nucleic acid is DNA (e.g., a linearized plasmid). Preferably, but not necessarily, the IL-15 portion of erLSP-IL-15 comprises a codon-optimized human IL-15 sequence.
[0011] In a further embodiment, the recombinant nucleic acid further comprises a second segment encoding CD16 or high affinity CD16, and / or may further comprise a third segment encoding a chimeric antigen receptor, and / or may further comprise a fourth segment encoding a protein that interferes with checkpoint inhibition, a protein that provides immune stimulation, a protein that binds / inhibits cytokines associated with immunosuppression, and / or an IL-15 receptor alpha chain. It is also contemplated that the recombinant nucleic acid comprises a promoter of sufficient strength to drive erLSP-IL-15 to be expressed in an amount sufficient to (a) render the modified NK cells independent of exogenous cytokines and (b) allow stimulation / activation of other immune competent cells near the modified NK cells. Optionally, the modified NK cells may comprise antibodies coupled to the cells via CD16.
[0012] In a further aspect of the present subject matter, the inventors also contemplate pharmaceutical compositions comprising a pharmaceutically acceptable carrier in combination with the genetically modified NK cells described herein. Most typically, such compositions will be formulated for infusion into a patient and may contain at least 1 x 10 9 cells.
[0013] Therefore, the inventors also contemplate the use of the genetically modified NK cells described herein in the treatment of cancer. Although this use may be cell infusion as a stand-alone treatment, other contemplated uses include administration of drugs that break through into the TME, administration of drugs that reduce immunosuppression, administration of drugs that stimulate immune competent cells, administration of cancer vaccine compositions, and / or administration of drugs that help maintain immune responses and promote the development of memory cells.
[0014] Various objects, features, aspects and advantages will become more apparent from the following detailed description of preferred embodiments and the accompanying drawings, in which like numerals represent like components. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 Depicted are exemplary graphs illustrating the growth rates of the various NK cells shown.
[0016] Figure 2 Exemplary results of immunophenotyping of NK cells are depicted as shown.
[0017] Figure 3-5 Exemplary results of cytotoxicity of various NK cells as indicated are depicted.
[0018] Figure 6-8 Further exemplary results of cytotoxicity of various NK cells are depicted as shown.
[0019] Fig. 9Depicted are schematic arrangements of exemplary recombinant nucleic acids used herein. DETAILED DESCRIPTION
[0020] The inventors have now found that modified NK cells can be generated, and the amount of recombinant IL-15 produced by them is sufficient to provide growth and stimulation independent of IL-2 / IL-15, while maintaining the cytotoxicity and functional expression of recombinant CD16 and / or CAR. In addition, in at least some embodiments, the modified NK cells considered will not only produce enough intracellular IL-15 (and especially erLSP-IL-15) to allow growth and expansion in the absence of cytokines, but also allow a certain amount of IL-15 to be secreted, and when such cells are present in the tumor microenvironment (TME), the amount of IL-15 contributes to the immune stimulation (or reversal of immunosuppression) in the TME. Therefore, the NK cells according to the subject matter of the present invention will advantageously allow simplified culture and expansion, while providing a pathway for recombinant targeted cytotoxicity through CD16 and / or CAR.
[0021] The previously prepared NK-92 derivatives expressing IL-2 with endoplasmic retention sequences are suspected to support the growth and expansion of immunosuppressive cells such as myeloid-derived suppressor cells (MDSC) and T regulatory cells (T-regs). These negative regulators can alleviate any anti-tumor effects of immune cells and especially aNK, haNK and t-haNK and donor NK cells. On the other hand, recombinant IL-15 only supports the function of immunocompetent cells, without negative effects on erIL-2.
[0022] However, it should be understood that the expression of IL-15 and its variants may have an adverse effect on the growth and / or function of NK cells and especially NK-92 cells. It is also not expected that the expression of biologically active forms of IL-15 and its variants, especially the amount of supporting cell expansion and activity, does not produce adverse interference to the recombinant proteins that are also required for targeting NK cells (such as CD16 and / or CAR). Still further, the overexpression and secretion of IL-15 and its variants exceeding the immunostimulatory level may cause systemic side effects of the receptors of such cells. From a different perspective, the preferred modified NK cells will produce and secrete sufficiently low IL-15 to avoid systemic side effects, but maintain the desired beneficial effects, growth and stimulation characteristics of modified cells and immune cells in TME. It is worth noting that the inventors now find that IL-15 formed and retained in the cell in an autocrine manner (i.e., without the need for exogenous cytokines) to stimulate growth and expansion can be prepared with NK cells having an ideal balance between secreted IL-15 and providing immunostimulatory effects to other immune competent cells in TME.
[0023] About suitable NK cells, it is generally considered that NK cells can be autologous NK cells from subjects who will receive genetically modified NK cells. Such autologous NK cells can be separated from whole blood, or cultured by precursor cells or stem cells using methods well known in the art. However, it should also be understood that NK cells do not need to be autologous, but can be allogeneic or xenogeneic NK cells. In a particularly preferred aspect of the subject matter of the present invention, genetically engineered NK cells are NK-92 cells or derivatives thereof. For example, in a particularly preferred aspect of the subject matter of the present invention, genetically engineered NK cells are NK-92 derivatives, which are modified to have the expression of at least one killer cell immunoglobulin-like receptor (KIR) reduced or eliminated, which will typically make such cells constitutively activated (via lack of inhibition or reduced inhibition).
[0024] NK-92 cells show unusual receptor expression profiles, expressing relatively large amounts of activated receptors (e.g., NKp30, NKp46, 2B4, NKGD, E, CD28). On the contrary, NK-92 cells also express few inhibitory receptors (e.g., NKGA / B, low levels of KIR2DL4, ILT-2), and lack most of the killer inhibitory receptors (KIR) cloned and expressed on normal NK cells. In addition, NK-92 expresses relatively high levels of molecules involved in the perforin-granzyme cytolysis pathway and other cytotoxic effector molecules (including tumor necrosis factor (TNF)-superfamily members FasL, TRAIL, TWEAK, TNF-α), indicating the ability to kill via alternative mechanisms. Moreover, NK-92 cells also express other molecules (CD80, CD86, CD40L, TRANCE) regulated by immune effector cells, and the correlation of these molecules in NK killing is unclear. However, it is worth noting that these particularly desirable features are not adversely affected by modification as described herein. Indeed, in at least some embodiments, as noted in more detail below, one or more of the above-described activators and / or effector proteins may be overexpressed in response to intracellular expression of IL-15.
[0025] Moreover, suitable NK cells may have one or more mutated modified KIR to reduce or eliminate the interaction with MHC class I molecules. Of course, it should be noted that one or more KIRs may also be deleted or their expression may be inhibited (e.g., by miRNA, siRNA, etc.). Most typically, more than one KIR will be mutated, deleted or silenced, and the KIRs considered in particular include those with two or three domains, with short or long cytoplasmic tails. From a different perspective, modified, silent or missing KIRs will include KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1, KIR3DL2, KIR3DL3, and KIR3DS1. Such modified cells can be prepared using protocols well known in the art. Alternatively, such cells can also be commercially obtained as aNK cells ('activated natural killer cells) from NantKwest (see URL www.nantkwest.com). Such cells can then be additionally genetically modified to express IL-15 or a variant thereof, as discussed further below.
[0026] In another preferred aspect of the subject matter of the present invention, genetically engineered NK cells can also be modified to express NK-92 derivatives of high-affinity Fcγ receptors (CD16). The sequences of high-affinity variants of Fcγ receptors are well known in the art (see, e.g., Blood [blood] 2009 113: 3716-3725), and all methods of production and expression are considered to be applicable to this article. It is believed that the expression of such receptors allows the use of antibodies specific to the patient's tumor cells (e.g., new epitopes), specific tumor types (e.g., her2neu, PSA, PSMA, etc.), or antibodies associated with cancer (e.g., CEA-CAM) to specifically target tumor cells. Advantageously, such antibodies are commercially available and can be used in conjunction with cells (e.g., in combination with Fcγ receptors). Alternatively, such cells can also be commercially available as haNK cells ('high-affinity natural killer cells) from NantKwest. Then, as discussed further below, such cells can be further genetically modified to express IL-15 or its variants.
[0027] Alternatively or additionally, genetically engineered NK cells may also be genetically engineered to express chimeric antigen receptors (CAR). In particularly preferred aspects, CAR will have scFv moieties or other extracellular domains with binding specificity for tumor-associated antigens, tumor-specific antigens, and cancer neo-epitopes. Therefore, as is readily understood, suitable CAR will include first-generation, second-generation, and third-generation CARs (see, for example, Immunotherapy [immunotherapy] (2015) 7 (5): 487-497). As previously mentioned, there are many ways in which genetically engineered NK cells express this chimeric T cell receptor, and it is believed that all methods are applicable herein. Alternatively, such cells may also be commercially available from NantKwest as taNK cells ('target-activated natural killer cells'). Then, as further discussed below, such cells may be further genetically modified to express IL-15 or its variants.
[0028] In the case of engineering cells to have affinity for cancer-associated antigens or antibodies specific for cancer-associated antigens, all known cancer-associated antigens are considered suitable for use. For example, cancer-associated antigens include CEA, MUC-1, CYPB1, etc. Similarly, in the case of engineering cells to have affinity for cancer-specific antigens or antibodies specific for cancer-specific antigens, all known cancer-specific antigens are considered suitable for use. For example, cancer-specific antigens include PSA, Her-2, PSA, brachyury, etc. In the case of engineering cells to have affinity for cancer neo-epitopes or antibodies specific for cancer neo-epitopes, all known ways of identifying neo-epitopes are considered to produce suitable targets. For example, whole genome analysis of tumor biopsies (or lymph biopsies or biopsies of metastatic sites) and matched normal tissues (i.e., non-diseased tissues from the same patient) can be performed, and neo-epitopes can be identified from patient tumors in the first step by synchronously comparing the omics information thus obtained. The identified new epitopes can then be further filtered for matching the patient's HLA type to increase the likelihood of new epitope antigen presentation. Most preferably, this matching can be done via computer simulation.
[0029] With regard to suitable IL-15 sequences for expression, it is generally preferred that the IL-15 is a mammalian IL-15 sequence, and most preferably a human IL-15 sequence (see, e.g., UniProt identifier P40933). In addition, it is noteworthy that suitable IL-15 sequences include various variants, and variants particularly contemplated include variants with long signal peptides (LSP) and short signal peptides (SSP). The LSP variant has a signal peptide of typically 48 amino acids, and the transcript typically includes a 5'-untranslated region (UTR) of 316 bases, a coding sequence of 486 bases, and a C-terminal 3'-UTR region of about 400 bases in length. The SSP variant has a short signal peptide of typically 21 amino acids, which is based on alternative splicing (encoded by exons 4A and 5). It is noteworthy that both isoforms produce the same mature protein, but cellular trafficking is different. More specifically, the IL-15 LSP isoform is detected in the Golgi apparatus, early endosomes and endoplasmic reticulum and can occur in secreted and membrane-bound forms. On the other hand, the IL-15 SSP isoform is not secreted and appears to be restricted to the cytoplasm and nucleus, where this isoform appears to be involved in the regulation of the cell cycle. As discussed below, still further contemplated IL-15 variants include superagonist variants, and in particular the IL-15 N72D mutant, which may or may not include additional signal peptides and / or trafficking signals.
[0030] Based on obvious differential signal transduction, the inventors therefore consider using various modifications to recombinant IL-15, thereby affecting the appropriate expression level and distribution and secretion amount in the cell. For this purpose, the inventors consider using each signal transduction part that can be fused with recombinant IL-15. For example, when IL-15 or IL-15 variants are exported to endosomes and lysosomes compartments, a leader peptide (such as a CD1b leader peptide) can be used to isolate (nascent) protein from the cytoplasm. Additionally or alternatively, a targeting presequence and / or a targeting peptide can be used. The presequence of the targeting peptide can be added to the N-terminal and / or C-terminal, and is typically included in basic amino acids and hydrophobic amino acids between 6-136. In the case of peroxisomal targeting, the targeting sequence can be at the C-terminal. Other signals (for example, signal spots) can be used, and sequence elements that are separated in the peptide sequence and work after the appropriate peptide folding are included. In addition, protein modifications such as glycosylation can induce targeting. Among other suitable targeting signals, the inventors consider peroxisome targeting signal 1 (PTS1), a C-terminal tripeptide, and peroxisome targeting signal 2 (PTS2), a nonapeptide located near the N-terminus.
[0031] Alternatively, protein sorting to endosomes and lysosomes can be mediated by signals within the cytosolic domain of the protein, which usually consist of short linear sequences. Some of these signals are known as tyrosine-based sorting signals and correspond to NPXY or Consensus motif. Other signals, called dileucine-based signals, also fit the [DE]XXXL[LI] or DXXLL consensus motifs. All of these signals are recognized by components of the protein coat associated with the periphery of the cytosolic surface of the membrane. [DE]XXXL[LI] and [DE]XXXL[LI] signals are recognized by the adaptor protein (AP) complexes AP-1, AP-2, AP-3, and AP-4 as having characteristic fine specificity, whereas DXXLL signals are recognized by another family of adaptor proteins called GGA. A FYVE domain may also be added, which is associated with vacuolar protein sorting and endosomal function. In still further aspects, endosomal compartments may also be targeted using human CD1 tail sequences (see, e.g., Immunology, 122, 522-531). For example, lysosomal targeting may be achieved using the LAMP1-TM (transmembrane) sequence; while circulating endosomes may be targeted via the CD1a tail targeting sequence; and sorting endosomes may be targeted via the CD1c tail targeting sequence.
[0032] Transport to or retention in the cytosol compartment does not necessarily require one or more specific sequence elements. However, in at least some aspects, an N- or C-terminal cytoplasmic retention signal can be added, including a membrane anchoring protein or a membrane anchoring domain of a membrane anchoring protein, so that the protein is retained in the cell facing the cytosol. For example, membrane anchoring proteins include SNAP-25, syntaxin, synaptobrevin, synaptotagmin, vesicle-associated membrane protein (VAMP), synaptic vesicle glycoprotein (SV2), high affinity choline transporter, neurotoxin, voltage-gated calcium channel, acetylcholinesterase and NOTCH.
[0033] In still further contemplated aspects of the inventive subject matter, IL-15 or IL-15 variants may also comprise one or more transmembrane segments that will direct the new epitope to the outside of the cell membrane after processing, thereby making it visible to immune competent cells. It is known in the art that there are numerous transmembrane domains, and all of these are considered suitable for use herein, including those having a single alpha helix, multiple alpha helices, alpha / beta barrel structures, and the like. For example, contemplated transmembrane domains can include the α, β, or ζ chains of a T cell receptor, CD28, CD3ε, CD45, CD4, CD5, CD8 (e.g., CD8α, CD8β), CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, KIRDS2, OX40, CD2, CD27, LFA-1 (CD11a, CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD40, BAFFR, HVEM (LIGHTR), SLAMF7, NKp80 (KLRF1), CD160, CD19, IL2Rβ, IL2Rγ, IL7Rα, ITGA1, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, One or more transmembrane domains of VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, TNFR2, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, or PAG / Cbp.
[0034] In addition, it is also considered that IL-15 or IL-15 variants can also be co-expressed with the IL-15 receptor α subunit. Such co-expression is considered to allow the binding or other association of IL-15 or IL-15 variants with the receptor α chain to stabilize IL-15 or IL-15 variants and / or contribute to the secretion or transportation / presentation of IL-15 or IL-15 variants on the surface of modified NK cells. Similarly, various other proteins (except CD16 and / or CAR) can be co-expressed with IL-15 or IL-15 variants, and suitable co-expressed proteins include various immunomodulatory compounds, and especially compounds that interfere with checkpoint inhibition (e.g., scFv for PD1, PD-L1, CTLA4, etc.), compounds that interfere with immune stimulation (e.g., IFN-γ, IL-12, IL-21, etc.) and / or compounds that bind / inhibit cytokines related to immunosuppression (e.g., TGF-β, IL-8, etc.).
[0035] As will be readily appreciated, IL-15 or IL-15 variants and other co-expressed proteins will be encoded on a recombinant nucleic acid, which may be one or more recombinant RNA or DNA molecules. However, most typically, the recombinant nucleic acid will be a polycistronic DNA construct, and preferably a plasmid. However, various other constructs are also considered suitable for use herein, and include viral vectors (which may be transfected as a virus or by other methods), linearized DNA, DNA bound to a vector (e.g., for projectile transfection), and the like.
[0036] Regardless of the specific configuration and type of nucleic acid, it is generally preferred that the modified NK-92 cells will express IL-15 or IL-15 variants in an amount that (a) makes the cells so transfected independent of exogenous cytokines and (b) allows stimulation / activation of other immune competent cells near the transfected cells (typically within the TME). For example, it is contemplated that secreted or otherwise extracellular (or extracellularly presented) recombinant IL-15 or IL-15 variants will account for 5%-10%, or 10%-20%, or 20%-30%, or 30%-50% of the total IL-15 or IL-15 variants produced in the cell. Thus, from a different perspective, secreted or otherwise extracellular (or extracellularly presented) recombinant IL-15 or IL-15 variants may be present in an amount between about 20-60 pg / ml, or about 60-80 pg / ml, or about 80-100 pg / ml, or about 100-150 pg / ml, or about 150-200 pg / ml, or even higher. On the other hand, it is contemplated that the intracellularly retained IL-15 or IL-15 variants may be present in an amount between about 100-150 pg / ml, or about 150-250 pg / ml, or about 250-500 pg / ml, or about 500-750 pg / ml, or higher. Thus, it should be noted that particularly preferred modified NK-92 cells will produce sufficient amounts of recombinant IL-15 or IL-15 variants to support autonomous growth and stimulation of immune competent cells in the TME, as well as to stimulate the establishment and maintenance of CD8+ T cell memory, but such amounts will not be sufficient to induce systemic adverse events in patients receiving such cells.
[0037] Therefore, from a functional perspective, recombinant IL-15 or IL-15 variants will be used to stimulate or enhance the effector functions and / or proliferation of other NK cells (e.g., autologous NK cells in TME), various T cells, etc., and enhance or trigger Jak / STAT signaling in cells in TME. In addition, due to the portion of IL-15 or IL-15 variants retained in the cells, as described in more detail below, such cells will also be able to proliferate in the absence of exogenous IL-2 and / or IL-15. In further considered aspects, such modified NK-92 cells will also have increased sensitivity to IL-12 signaling compared to unmodified NK-92 cells, which can reduce IL-4-mediated IFN-γ inhibition, which in turn can reduce Th1T cell inhibition in TME.
[0038] The modified NK cells considered are preferably used to treat diseases that respond to the administration of NK cells, especially for the treatment of various cancers. As will be readily understood, modified NK cells can be used as the sole therapeutic agent or as a medicament in a more complex scheme. For example, modified NK cells can be part of an immunotherapy strategy, in which tumors can first be treated with drugs (e.g., abraxane) that break through into the TME, drugs that reduce immunosuppression (e.g., cyclophosphamide), drugs that stimulate various immune-competent cells (e.g., ALT-803), and cancer vaccine compositions (e.g., recombinant AdV encoding tumor neoantigens), and / or with drugs that help maintain immune responses and promote memory cell development (e.g., tumor-targeted IL-12) treatment. Exemplary suitable treatment regimens are discussed in WO 2018 / 005973, incorporated herein by reference.
[0039] Regarding appropriate dosage and mode of administration, it is generally preferred that the amount of cells and the infusion schedule generally follow known established protocols for infusion of NK cells. Thus, a typical amount of modified NK-92 cells would be between 5×10 7 cells / dose IV and 5×10 8 cells / dose IV, or between 5×10 8 cells / dose IV and 5×10 9 cells / dose IV, or between 5×10 9 cells / dose IV and 5×10 10 cells / dose IV, and most typically between 7 × 10 8 cells / dose IV and 7×10 9 cells / dose IV (e.g., 2×10 9 Of course, it should be understood that where the modified NK cells express CD16 or a high affinity variant of CD16 (e.g., 158V), the cells can be co-administered with one or more antibodies that advantageously bind to the modified NK cells (either in vitro prior to infusion or sequentially, e.g., with antibodies administered prior to infusion of the cells).
[0040] Examples
[0041] The following examples are provided for representative guidance only and should not be construed as limiting the subject matter of the present invention. Unless otherwise specified, all recombinant expression constructs used a codon-optimized version of IL-15 as shown in SEQ ID NO: 1, which in at least some embodiments provided higher recombinant protein yields (data not shown).
[0042] In the first set of experiments, three IL-15 variants were created using SEQ ID NO: 1: a long signal peptide variant corresponding to wild-type IL-15 (LSP-IL-15), a long signal peptide variant with an ER retention signal (erLSP-IL15), and a short signal peptide variant as an alternative splice variant (SSP-IL-15). More specifically, in one embodiment, IL-15LSP has a nucleotide sequence as shown in SEQ ID NO: 2; IL-15LSP has a peptide sequence of SEQ ID NO: 3; erIL-15LSP has a nucleotide sequence of SEQ ID NO: 4; erIL-15LSP has a peptide sequence of SEQ ID NO: 5; IL-15SSP has a nucleotide sequence of SEQ ID NO: 6; IL-15 has a peptide sequence of SEQ ID NO: 7.
[0043] Plasmid design and transfection:
[0044] Three gBlocks flanked by KpnI / NotI restriction enzyme sites were synthesized by Integrated DNA Technologies and used to subclone each sequence into a similarly digested pNEUkv1-CD16-erIL2 plasmid backbone to create the following plasmids.
[0045] pNEUkv1-CD16(158V)-IRES-(KpnI)-[IL-15LSP]-(NotI)
[0046] pNEUkv1-CD16(158V)-IRES--(KpnI)-[erIL-15LSP]-(NotI)
[0047] pNEUkv1-CD16(158V)-IRES--(KpnI)-[IL-15SSP]-(NotI)
[0048] All plasmids were confirmed by Sanger sequencing, linearized by SalI restriction enzyme digestion, and isolated by column purification. 1 μg of linearized DNA / 10 6Cell lines were created using 10 cells per well. pNEUkv1-CD16-IRES-[erIL-2] was similarly prepared and electroporated as a positive control. The experiment was repeated twice to confirm the results. A NK-92 cell line co-expressing CD16 and erIL-15 was created by electroporating the following linearized plasmid aNK (NK-92 "wild type"): pNEUkv1-CD16(158V)-IRES-[LSPIL-15]; pNEUkv1-CD16(158V)-IRES-[erIL-15]; and pNEUkv1-CD16(158V)-IRES-[SSP IL-15]. The positive control was transfected with pNeukv1-CD16-IRES-[erIL-2]. All samples were incubated in X-vivo-10 / 5% HS without any cytokines for 2 weeks.
[0049] To determine the successful transfection of the plasmid, the electroporated cells were grown for 2 weeks in X-vivo-10 with 5% HS without any cytokines. Remarkably, only one of the three IL-15 clones tested successfully grew back: the long signal peptide with ER retention signal (erIL-15). In addition, as shown in more detail below, NK-92 cells expressing erIL-15 (erLSP-IL15) maintained all relevant NK surface markers and cytotoxicity. In addition, these cells also provide an ideal amount of extracellular erLSP-IL15 that retains its immunostimulatory biological function, most likely after removing the er / LSP segment from mature IL-15.
[0050] from Figure 1 It can be seen that the expression of erIL-15 does not alter the growth rate of cells expressing erLSP-IL-15 in the absence of exogenous cytokines compared to aNK or haNK (CD16+, erIL-2) cells. Therefore, recombinant expression of erLSP-IL-15 advantageously provides sufficient autocrine signaling to support cell expansion. This result is unexpected because the ER retention sequence may not be removed within the cell but still maintain proper function. In addition, recombinant expression of erLSP-IL-15 does not adversely affect many phenotypic markers of the modified N-92 cells. Exemplary results of the immunophenotype of the newly generated cell line are shown in Figure 2 Here, the flow cytometry surface receptor profile tested was identical to that of haNK cells, a CD16 expressing NK-92 cell line co-expressing erIL2.
[0051] In this context, it should be appreciated that the newly created cell lines maintain full expression of functionally critical surface proteins: CD16 (Fc receptor) and the activating receptor NKG2D. To test the functionality of the cell lines expressing erIL-15 and compare with the cell line expressing erIL-2 (haNK), cytotoxicity assays were performed using different target cell lines: K562, Raji and HL-60. Figure 3-5 The results shown in clearly demonstrate that the introduction of erIL-15 did not alter the spontaneous cytotoxic properties compared to haNK cells. This is an unexpected finding, as the integration of new / different genes could affect the cytotoxic function of NK-92 cells. Figure 3-5 It can also be seen in Figure 3 that at the same effector cell to target cell ratio, cells expressing erIL-15 outperform cells expressing erIL-2.
[0052] To further test whether the new erIL-15-based plasmid can be incorporated into the tricistronic CAR expression plasmid without affecting CAR activity, NK-92 cell lines were generated by electroporation with tricistronic CAR_CD16_erIL-15 plasmids encoding CD19CAR, CD20CAR or CD33CAR. The cytotoxic function of the cell lines expressing erIL-15 was tested and compared with the cytotoxic function of the corresponding t-haNK cells (erIL-2) against several target cell lines: K562 (CD19neg, CD20neg, CD33+), SUPB15 CD20 (CD20+), THP-1(CD33+). Figure 6-8 Exemplary results are illustrated. Here, the killing of K562 by the transfected (tricistronic) cell line in the above figure shows excellent killing effect under all tested effectors:target ratios. This result is important because the new construct does not affect the killing of the standard K562 line (top figure). Importantly, the newly created CAR can kill target cell lines expressing CD20 and CD33, which are resistant to the killing of wild-type NK-92.
[0053] In yet further experiments, the resilience and functionality of erLSP-IL-15 cells will be assessed. For example, previously frozen erIL-2CD19 t-haNK and erIL-15CD19 t-haNK will be thawed and then grown in X-Vivo 105% without cytokines. In the absence of exogenously added cytokines, the survival and expansion properties of both cell lines are comparable.
[0054] In yet further experiments, IL-15 and IL-2 secretion will be measured. Here, it is considered that IL-15 secretion will be equal to or better than IL-2 secretion by at least 5%, or at least 10%, or at least 20%, or at least 40%, or even higher, especially in the case where the cells also co-express the IL-15 receptor α chain. Quantitatively, it is expected that the modified NK=92 cells will secrete at least 100pg / ml, or at least 150pg / ml, or at least 200pg / ml, or even higher IL-15, and the intracellular amount (determined by lysate) will be at least 150pg / ml, or at least 250pg / ml, or at least 500pg / ml, or at least 750pg / ml, or even higher.
[0055] In addition, it is expected that the modified NK-92 cells as described herein will not show agglomeration or other aggregation during expansion and culture. Similarly, compared with the doubling time of aNK cells or haNK cells when using standard growth assays, the cells described herein (and in particular cells expressing CD16 (preferably high affinity variants) and / or CAR) will have substantially the same doubling time (i.e., a deviation of no more than 15%, or no more than 10%, or no more than 5%). Similarly, compared with haNK cells and t-haNK cells, cells expressing erLSP-IL-15 generally express functionally active recombinant CAR and / or CD16 in substantially similar amounts (i.e., a deviation of no more than 15%, or no more than 10%, or no more than 5%).
[0056] Similarly, it is expected that cells expressing erLSP-IL-15 and recombinant CAR and / or CD16 will have essentially the same non-specific cytotoxicity against K562 as aNK and haNK cells. As shown above, NK-92 cells expressing erLSP-IL-15 and recombinant CAR are expected to be as CAR-mediated killing of SUP-B15 cells as ADCC-mediated killing of SUPB15 CD20+ cells.
[0057] From a functional point of view, the modified NK-92 cells considered herein will have comparable or enhanced IFNγ secretion with or without target stimulation (or cytokine panel IFNγ / IL-8 / IL-10 / chemokines). In addition, it is expected that the modified NK-92 cells considered herein will have comparable or enhanced flow markers (NKp30, NKp44, NKp46, DNAM-1, NKG2D, NKG2A, NKG2C, CD94, CD96, TIGIT, PD-1, PD-L1, CTLA-4, TIM-3, LAG-3, FasL, TRAIL, T-bet, Eomes, granzyme B, perforin) expression.
[0058] In still further contemplated methods, RNA seq analysis will be performed to identify expression patterns that can be used to track the activity and / or presence of modified NK-92 cells within tumors, as well as the presence and / or activity of other immune competent cells. RNA seq analysis is expected to provide RNA expression patterns that are substantially representative of activated NK cells.
[0059] As used herein, the term "administering" a pharmaceutical composition or drug refers to direct and indirect administration of a pharmaceutical composition or drug, wherein direct administration of a pharmaceutical composition or drug is typically performed by a health care professional (e.g., a physician, a nurse, etc.), and wherein indirect administration includes providing the pharmaceutical composition or drug to a health care professional or making the pharmaceutical composition or drug available to a health care professional for direct administration (e.g., via injection, infusion, oral delivery, local delivery, etc.). Most preferably, the cells or exosomes are administered via subcutaneous or subdermal injection. However, in other contemplated aspects, administration may also be intravenous injection. Alternatively or additionally, antigen presenting cells may be isolated or grown from cells of a patient, infected in vitro, and then infused into the patient. Therefore, it should be understood that the systems and methods contemplated may be viewed as complete drug discovery systems (e.g., drug discovery, treatment regimens, validation, etc.) for highly personalized cancer therapy.
[0060] The description of the range of values herein is intended only to be used as a shorthand method for individually referring to each individual value falling within the range. Unless otherwise specified in this article, each individual value is incorporated into the specification as if it were individually quoted in this article. Unless otherwise indicated in this article or otherwise clearly contradictory to the context, all methods described herein can be performed in any suitable order. The application of any and all examples or exemplary language (such as "for example") provided with respect to certain embodiments herein is intended only to better illustrate the full scope of this disclosure, without limiting the scope of the invention claimed in addition. Any language in this specification should not be interpreted as indicating that any unclaimed element is necessary for practicing the claimed invention.
[0061] It should be clear to those skilled in the art that, without departing from the full scope of the concepts disclosed herein, in addition to those already described, many other modifications may also be made. Therefore, the present disclosure subject matter is limited only to the scope of the appended claims. In addition, when interpreting this specification and claims, all terms should be interpreted in a manner as broad as possible consistent with the context. In particular, the term "comprises" and "comprising" should be interpreted as referring to elements, components or steps in a non-exclusive manner, thereby indicating that the mentioned elements, components or steps can exist, or use, or combine with other elements, components or steps not explicitly mentioned. In the case where the claims of this specification refer to at least one of something selected from the group consisting of A, B, C ... and N, the text should be interpreted as requiring only one element in the group, rather than A plus N or B plus N, etc.
Claims
1. A recombinant nucleic acid comprising a first segment encoding erLSP-IL-15, wherein the nucleic acid comprises SEQ ID NO:
4.
2. The recombinant nucleic acid of claim 1, wherein the recombinant nucleic acid is selected from the group consisting of DNA, a polycistronic DNA construct, a plasmid, a viral vector, RNA, and a linearized plasmid.
3. The recombinant nucleic acid according to claim 1 or 2, wherein the recombinant nucleic acid further comprises a second segment encoding CD16 or high affinity CD16.
4. The recombinant nucleic acid according to claim 1 or 2, wherein the recombinant nucleic acid further comprises a third segment encoding a chimeric antigen receptor.
5. The recombinant nucleic acid according to claim 1 or 2, wherein the recombinant nucleic acid further comprises a fourth segment encoding a protein that interferes with checkpoint inhibition, a protein that provides immune stimulation, a protein that binds and inhibits cytokines associated with immunosuppression, and / or an IL-15 receptor α chain.
6. The recombinant nucleic acid according to claim 1 or 2, wherein the IL-15 portion in the erLSP-IL-15 comprises a codon-optimized human IL-15 sequence.
7. A method for genetically modifying immune cells in vitro, the method comprising: A recombinant nucleic acid is introduced into the immune cell to obtain a genetically modified immune cell, wherein the recombinant nucleic acid comprises a first segment encoding erLSP-IL-15, wherein the first segment comprises SEQ ID NO:
4.
8. The method of claim 7, wherein the immune cell is an antigen presenting cell.
9. The method of claim 8, wherein the antigen presenting cells are dendritic cells.
10. The method of claim 7, wherein the immune cells are natural killer (NK) cells.
11. The method of claim 7, wherein the recombinant nucleic acid is a viral vector.
12. The method of claim 7, wherein the recombinant nucleic acid is an RNA molecule.
13. The method of claim 7, wherein the recombinant nucleic acid is a linearized plasmid.
14. The method of claim 7, wherein the recombinant nucleic acid further comprises a second segment encoding CD16 or high affinity CD16.
15. The method of claim 14, wherein the recombinant nucleic acid further comprises a third segment encoding a chimeric antigen receptor.
16. The method of claim 15, wherein the recombinant nucleic acid further comprises a protein encoding a protein that interferes with checkpoint inhibition, a protein that provides immune stimulation, a protein that binds / inhibits cytokines associated with immunosuppression, and / or a fourth segment of the IL-15 receptor alpha chain.
17. The method of claim 7, wherein the recombinant nucleic acid comprises a promoter of sufficient strength to drive expression of the erLSP-IL-15 in an amount sufficient to allow stimulation / activation of other immune competent cells in proximity to the genetically modified immune cell.
18. The method of claim 7, wherein the IL-15 portion of the erLSP-IL-15 comprises a codon-optimized human IL-15 sequence.
19. A pharmaceutical composition comprising a pharmaceutically acceptable carrier in combination with a genetically modified immune cell as defined in any one of claims 7 to 18.
20. The pharmaceutical composition of claim 19, formulated for infusion into a patient.
21. The pharmaceutical composition according to claim 19, comprising at least 5 x 10 7 cells.
22. A pharmaceutical composition for treating cancer, comprising the genetically modified immune cell as defined in any one of claims 7 to 18.
23. A pharmaceutical composition for preparing a drug for stimulating a cell-mediated immune response, the composition comprising genetically modified natural killer NK cells, the genetically modified natural killer NK cells comprising a recombinant nucleic acid containing a first segment, the first segment encoding a long signal peptide LSP variant of interleukin-15 (IL-15) shown in SEQ ID NO: 5, wherein the variant comprises an endoplasmic reticulum retention signal erLSP-IL-15.
24. The composition of claim 23, further comprising a formulation of at least one drug selected from a drug that breaks through into the tumor microenvironment (TME), a drug that reduces immunosuppression, a drug that stimulates immune competent cells, a cancer vaccine, and a drug that promotes the development of memory cells.
25. The composition of claim 24, wherein the drug that breaks through into the TME comprises avasalen.
26. The composition of claim 24, wherein the drug that reduces immunosuppression is cyclophosphamide.
27. The composition of claim 24, wherein the drug that stimulates immune competent cells is ALT-803.
28. The composition of claim 24, wherein the cancer vaccine is an adenovirus V (Adv)-based vaccine comprising a nucleic acid encoding at least one of a tumor-associated antigen, a tumor-specific antigen, or a neoantigen.
29. The composition of claim 24, wherein the drug that promotes memory cell development is a tumor-targeted IL-12 fusion construct.
30. The composition of claim 23, wherein the NK cells are formulated for intravenous (IV) administration.
31. The composition according to claim 23, wherein the NK cells are formulated at 5×10 7 cells / dose IV to 5 × 10 10 The dose was administered at 1 cell / dose IV.
Citation Information
Patent Citations
Nant cancer vaccine
WO2018005973A1
Cited By
Method for amplifying NK (Natural Killer) cells in vitro by utilizing extracellular vesicles of artificial antigen presenting cells
CN120192929A
